What is HC Wainwright’s Estimate for Climb Bio Q1 Earnings?

Climb Bio, Inc. (NASDAQ:CLYM) – Analysts at HC Wainwright cut their Q1 2026 EPS estimates for Climb Bio in a research report issued on Tuesday, March 10th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.28) per share for the quarter, down from their previous forecast of ($0.18). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Climb Bio’s Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.08) EPS and FY2027 earnings at ($1.18) EPS.

CLYM has been the subject of several other reports. Wedbush initiated coverage on shares of Climb Bio in a report on Thursday, March 5th. They issued an “outperform” rating and a $12.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, January 21st. Raymond James Financial initiated coverage on Climb Bio in a research report on Tuesday. They set a “strong-buy” rating on the stock. Robert W. Baird raised their price target on Climb Bio from $9.00 to $12.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Finally, Piper Sandler assumed coverage on Climb Bio in a research report on Friday, February 13th. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.40.

Climb Bio Price Performance

NASDAQ CLYM opened at $7.33 on Thursday. The firm has a market cap of $499.79 million, a P/E ratio of -8.24 and a beta of -0.25. The company’s 50 day moving average is $5.39 and its 200-day moving average is $3.43. Climb Bio has a 12-month low of $1.05 and a 12-month high of $8.04.

Climb Bio (NASDAQ:CLYM) last issued its earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06).

Insider Activity at Climb Bio

In other news, Director Ra Capital Management, L.P. acquired 101,462 shares of Climb Bio stock in a transaction that occurred on Friday, December 12th. The stock was bought at an average price of $2.86 per share, with a total value of $290,181.32. Following the completion of the purchase, the director owned 3,396,318 shares in the company, valued at approximately $9,713,469.48. The trade was a 3.08% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.80% of the company’s stock.

Institutional Trading of Climb Bio

Several institutional investors and hedge funds have recently bought and sold shares of CLYM. AQR Capital Management LLC bought a new position in Climb Bio in the 1st quarter valued at $27,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Climb Bio during the 3rd quarter valued at $29,000. Qube Research & Technologies Ltd bought a new position in shares of Climb Bio in the second quarter worth $43,000. Virtu Financial LLC purchased a new stake in shares of Climb Bio in the fourth quarter worth $43,000. Finally, Blair William & Co. IL purchased a new stake in shares of Climb Bio in the fourth quarter worth $44,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

Key Climb Bio News

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: HC Wainwright raised its price target on CLYM from $11 to $15 and kept a “Buy” rating — a large upside vs. the current share price, which is likely the main bullish catalyst for the stock today. Benzinga Article
• Neutral Sentiment: HC Wainwright published quarterly EPS estimates for FY2027 (Q1: -$0.26, Q2: -$0.29, Q3: -$0.31, Q4: -$0.32) and a full‑year consensus of about -$1.57. These are model-driven projections that reaffirm expected losses but also provide a roadmap for investor expectations. MarketBeat Report
• Negative Sentiment: Reports flagged a “large increase” in March short interest, but the published figures show 0 shares and NaN changes with a 0.0 days-to-cover — indicating likely data/reporting errors. If confirmed as a real short build, it could add downward pressure; as-is, the ambiguity may fuel volatility and speculative trading.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.